NCT01706224CompletedNot Applicable
Sero-prevalence of Pertussis Antibodies and Disease Awareness Among Healthcare Professionals in Spain
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- GlaxoSmithKline
- Enrollment
- 757
- Locations
- 1
- Primary Endpoint
- Evaluation of the overall sero-prevalence of Bordetella pertussis infection among subjects with respect to anti-pertussis (anti-PT) antibody levels.
Study Overview
Brief Summary
This study aims to determine the sero-prevalence of anti-pertussis antibodies among healthcare professionals at hospital centres in Spain.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Cross Sectional
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Written informed consent obtained from the subject.
- •Subjects who the investigator believes that they can and will comply with the requirements of the protocol.
- •Male and female healthcare professionals aged ≥18 years from selected hospitals.
- •Healthcare professionals in frequent contact with patients in the hospitals.
- •Agreeing for collection of a blood sample for the study.
Exclusion Criteria
- •Medical students working as healthcare professionals.
Outcomes
Primary Outcomes
Evaluation of the overall sero-prevalence of Bordetella pertussis infection among subjects with respect to anti-pertussis (anti-PT) antibody levels.
Time Frame: Day 0 of each subject at the time of enrollment.
Evaluation of the overall sero-prevalence of Bordetella pertussis infection among subjects with respect to anti-PT seronegativity status.
Time Frame: Day 0 of each subject at the time of enrollment.
Evaluation of the overall sero-prevalence of Bordetella pertussis infection among subjects with respect to anti-PT seropositivity status.
Time Frame: Day 0 of each subject at the time of enrollment.
Secondary Outcomes
- Description of the household composition of healthcare professionals to identify the proportion of healthcare professionals potentially at a higher risk of contracting and transmitting pertussis.(Day 0 of each subject at the time of enrollment.)
- Evaluation of the sero-prevalence of B. pertussis antibodies among healthcare professionals aged ≥ 18 years.(Day 0 of each subject at the time of enrollment.)
- Evaluation of the sero-prevalence of anti-pertussis antibodies among healthcare professionals by vaccination history.(Day 0 of each subject at the time of enrollment.)
- Evaluation of the sero-prevalence of anti-pertussis antibodies among healthcare professionals by previous history of pertussis.(Day 0 of each subject at the time of enrollment.)
- Description of the knowledge and beliefs about whooping cough and vaccination against pertussis among healthcare professionals.(Day 0 of each subject at the time of enrollment.)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Early Phase 1
Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibody Response After a Single Dose of Tdap in Pregnant Thai WomenPregnancy RelatedPertussisNCT03498300Mahidol University129
Unknown
Not Applicable
Seroprevalence of Pertussis Among Children and Adolescents in CroatiaImmunogenicity, VaccineNCT04725669University Hospital for Infectious Diseases, Croatia1,500
Completed
Not Applicable
Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis VaccinesPertussisNCT01129362Sanofi Pasteur, a Sanofi Company1,195
Recruiting
Not Applicable
Prevalence and Impact of Pertussis and RSV on Asthma Severity and ControlRSV InfectionAsthmaPertussisNCT06286007Hospital Clinico Universitario de Santiago784
Unknown
Phase 4
Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid ArthritisRheumatoid ArthritisNCT01301703Tel-Aviv Sourasky Medical Center100